Lipoprotein Combine Index as a Better Marker for NAFLD Identification Than Traditional Lipid Parameters

References

• Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212–2224. doi:10.1016/S0140-6736(20)32511-3
   PubMed Web of Science ®Google Scholar
• Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med Lond. 2018;18:245–250. doi:10.7861/clinmedicine.18-3-245
   PubMed Web of Science ®Google Scholar
• Le MH, Le DM, Baez TC, et al. Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol. 2023;79:287–295. doi:10.1016/j.jhep.2023.03.040
   PubMed Web of Science ®Google Scholar
• Younossi ZM. Non-alcoholic fatty liver disease – a global public health perspective. J Hepatol. 2019;70(3):531–544. doi:10.1016/j.jhep.2018.10.033
   PubMed Web of Science ®Google Scholar
• Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67:829–846. doi:10.1016/j.jhep.2017.05.016
   PubMed Web of Science ®Google Scholar
• Nseir W, Hellou E, Assy N. Role of diet and lifestyle changes in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:9338–9344. doi:10.3748/wjg.v20.i28.9338
   PubMed Web of Science ®Google Scholar
• Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263–2273. doi:10.1001/jama.2015.5370
   PubMed Web of Science ®Google Scholar
• Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism. 2016;65:1109–1123. doi:10.1016/j.metabol.2016.05.003
   PubMed Web of Science ®Google Scholar
• Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999–2014.e1. doi:10.1053/j.gastro.2019.11.312
   PubMed Web of Science ®Google Scholar
• Speliotes EK, Massaro JM, Hoffmann U, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham heart study. Hepatology. 2010;51:1979–1987. doi:10.1002/hep.23593
   PubMed Web of Science ®Google Scholar
• Sheng G, Liu D, Kuang M, et al. Utility of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio in evaluating incident diabetes risk. Diabetes Metab Syndr Obes. 2022;15:1677–1686. doi:10.2147/DMSO.S355980
   PubMed Web of Science ®Google Scholar
• Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis. 2012;32:22–29. doi:10.1055/s-0032-1306423
   PubMed Web of Science ®Google Scholar
• Cohen DE, Fisher EA. Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease. Semin Liver Dis. 2013;33:380–388. doi:10.1055/s-0033-1358519
   PubMed Web of Science ®Google Scholar
• Peng K, Mo Z, Tian G. Serum lipid abnormalities and nonalcoholic fatty liver disease in adult males. Am J Med Sci. 2017;353:236–241. doi:10.1016/j.amjms.2017.01.002
   PubMed Web of Science ®Google Scholar
• Zhang QQ, Lu LG. Nonalcoholic fatty liver disease: dyslipidemia, risk for cardiovascular complications, and treatment strategy. J Clin Transl Hepatol. 2015;3:78–84. doi:10.14218/JCTH.2014.00037
   PubMedGoogle Scholar
• Gaggini M, Morelli M, Buzzigoli E, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5:1544–1560. doi:10.3390/nu5051544
   PubMed Web of Science ®Google Scholar
• Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75:3313–3327. doi:10.1007/s00018-018-2860-6
   PubMed Web of Science ®Google Scholar
• Jones JG. Hepatic glucose and lipid metabolism. Diabetologia. 2016;59:1098–1103. doi:10.1007/s00125-016-3940-5
   PubMed Web of Science ®Google Scholar
• Yu S, Yan L, Yan J, et al. The predictive value of nontraditional lipid parameters for intracranial and extracranial atherosclerotic stenosis: a hospital-based observational study in China. Lipids Health Dis. 2023;22:16. doi:10.1186/s12944-022-01761-4
   PubMed Web of Science ®Google Scholar
• Li Y, Feng Y, Li S, et al. The atherogenic index of plasma (AIP) is a predictor for the severity of coronary artery disease. Front Cardiovasc Med. 2023;10:1140215. doi:10.3389/fcvm.2023.1140215
   PubMed Web of Science ®Google Scholar
• Çelik E, Çora AR, Karadem KB. The effect of untraditional lipid parameters in the development of coronary artery disease: atherogenic index of plasma, atherogenic coefficient and lipoprotein combined index. J Saudi Heart Assoc. 2021;33:244–250. doi:10.37616/2212-5043.1266
   PubMed Web of Science ®Google Scholar
• Cai G, Shi G, Xue S, et al. The atherogenic index of plasma is a strong and independent predictor for coronary artery disease in the Chinese Han population. Medicine. 2017;96:e8058. doi:10.1097/MD.0000000000008058
   PubMed Web of Science ®Google Scholar
• Svegliati-Baroni G, Pierantonelli I, Torquato P, et al. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease. Free Radic Biol Med. 2019;144:293–309. doi:10.1016/j.freeradbiomed.2019.05.029
   PubMed Web of Science ®Google Scholar
• Musso G, Cassader M, Paschetta E, et al. Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis. Gastroenterology. 2018;155:282–302.e8. doi:10.1053/j.gastro.2018.06.031
   PubMed Web of Science ®Google Scholar
• Okamura T, Hashimoto Y, Hamaguchi M, et al. Ectopic fat obesity presents the greatest risk for incident type 2 diabetes: a population-based longitudinal study. Int J Obes Lond. 2019;43:139–148. doi:10.1038/s41366-018-0076-3
   PubMed Web of Science ®Google Scholar
• Choi JH, Sohn W, Cho YK. The effect of moderate alcohol drinking in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2020;26:662–669. doi:10.3350/cmh.2020.0163
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502. doi:10.1093/clinchem/18.6.499
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Hamaguchi M, Kojima T, et al. Modest alcohol consumption reduces the incidence of fatty liver in men: a population-based large-scale cohort study. J Gastroenterol Hepatol. 2015;30:546–552. doi:10.1111/jgh.12786
   PubMed Web of Science ®Google Scholar
• Aaron DJ, Kriska AM, Dearwater SR, et al. Reproducibility and validity of an epidemiologic questionnaire to assess past year physical activity in adolescents. Am J Epidemiol. 1995;142:191–201. doi:10.1093/oxfordjournals.aje.a117618
   PubMed Web of Science ®Google Scholar
• Ryu S, Chang Y, Kim DI, et al. gamma-Glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. Clin Chem. 2007;53:71–77. doi:10.1373/clinchem.2006.078980
   PubMed Web of Science ®Google Scholar
• Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102:2708–2715. doi:10.1111/j.1572-0241.2007.01526.x
   PubMed Web of Science ®Google Scholar
• Box GEP, Cox DR. An analysis of transformations. J Royal Statist Soc Seri. 1964;26:211–243. doi:10.1111/j.2517-6161.1964.tb00553.x
   Google Scholar
• Yu H, Sang P, Huan T. Adaptive box-cox transformation: a highly flexible feature-specific data transformation to improve metabolomic data normality for better statistical analysis. Anal Chem. 2022;94:8267–8276. doi:10.1021/acs.analchem.2c00503
   PubMed Web of Science ®Google Scholar
• Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology. 2003;14:680–686. doi:10.1097/01.EDE.0000081989.82616.7d
   PubMed Web of Science ®Google Scholar
• Muanda FT, Weir MA, Bathini L, et al. Association of baclofen with encephalopathy in patients with chronic kidney disease. JAMA. 2019;322:1987–1995. doi:10.1001/jama.2019.17725
   PubMed Web of Science ®Google Scholar
• Kim JH. Multicollinearity and misleading statistical results. Korean J Anesthesiol. 2019;72:558–569. doi:10.4097/kja.19087
   PubMed Web of Science ®Google Scholar
• Fitchett EJA, Seale AC, Vergnano S, et al. Strengthening the reporting of observational studies in epidemiology for newborn infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16:e202–e213. doi:10.1016/S1473-3099(16)30082-2
   PubMed Web of Science ®Google Scholar
• Dyussenbayev A. Age periods of human life. Adv Social Sci Res J. 2017;4. doi:10.14738/assrj.46.2924
   Google Scholar
• WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–163. doi:10.1016/S0140-6736(03)15268-3
   PubMed Web of Science ®Google Scholar
• DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–845. doi:10.2307/2531595
   PubMed Web of Science ®Google Scholar
• Yeh TS, Yuan C, Ascherio A, et al. Long-term dietary flavonoid intake and subjective cognitive decline in US men and women. Neurology. 2021;97:e1041–e1056. doi:10.1212/WNL.0000000000012454
   PubMed Web of Science ®Google Scholar
• Zhang YB, Chen C, Pan XF, et al. Associations of healthy lifestyle and socioeconomic status with mortality and incident cardiovascular disease: two prospective cohort studies. BMJ. 2021;373:n604. doi:10.1136/bmj.n604
   PubMedGoogle Scholar
• Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908–922. doi:10.1038/s41591-018-0104-9
   PubMed Web of Science ®Google Scholar
• Östlund C, Hernandez-Ono A, Shin JY. The nuclear envelope in lipid metabolism and pathogenesis of NAFLD. Biology. 2020;9:338. doi:10.3390/biology9100338
   PubMedGoogle Scholar
• Mungamuri SK, Sinha SN, Javvadi Y. Understanding the alterations in lipid metabolism in NAFLD progression: current trends and future directions. Crit Rev Oncog. 2021;26:35–49. doi:10.1615/CritRevOncog.2020035839
   PubMedGoogle Scholar
• Martin A, Lang S, Goeser T, et al. Management of dyslipidemia in patients with non-alcoholic fatty liver disease. Curr Atheroscler Rep. 2022;24:533–546. doi:10.1007/s11883-022-01028-4
   PubMed Web of Science ®Google Scholar
• Souza MR, Diniz Mde F, Medeiros-Filho JE, et al. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol. 2012;49:89–96. doi:10.1590/s0004-28032012000100015
   PubMedGoogle Scholar
• Cho HC. Prevalence and factors associated with nonalcoholic fatty liver disease in a nonobese Korean population. Gut Liver. 2016;10:117–125. doi:10.5009/gnl14444
   PubMed Web of Science ®Google Scholar
• Tang Z, Pham M, Hao Y, et al. Sex, Age, and BMI modulate the association of physical examinations and blood biochemistry parameters and NAFLD: a retrospective study on 1994 cases observed at Shuguang hospital, China. Biomed Res Int. 2019;2019:1246518. doi:10.1155/2019/1246518
   PubMed Web of Science ®Google Scholar
• Li Q, Zhang X, Zhang C, et al. Risk factors and prediction models for nonalcoholic fatty liver disease based on random forest. Comput Math Methods Med. 2022;2022:8793659. doi:10.1155/2022/8793659
   PubMed Web of Science ®Google Scholar
• Ren XY, Shi D, Ding J, et al. Total cholesterol to high-density lipoprotein cholesterol ratio is a significant predictor of nonalcoholic fatty liver: jinchang cohort study. Lipids Health Dis. 2019;18:47. doi:10.1186/s12944-019-0984-9
   PubMed Web of Science ®Google Scholar
• Cheng Y, Zhang Q, Li H, et al. Remnant cholesterol, stronger than triglycerides, is associated with incident non-alcoholic fatty liver disease. Front Endocrinol. 2023;14:1098078. doi:10.3389/fendo.2023.1098078
   PubMed Web of Science ®Google Scholar
• Wang G, Shen X, Wang Y, et al. Analysis of risk factors related to nonalcoholic fatty liver disease: a retrospective study based on 31,718 adult Chinese individuals. Front Med Lausanne. 2023;10:1168499. doi:10.3389/fmed.2023.1168499
   PubMed Web of Science ®Google Scholar
• Mahdavi-Roshan M, Mozafarihashjin M, Shoaibinobarian N, et al. Evaluating the use of novel atherogenicity indices and insulin resistance surrogate markers in predicting the risk of coronary artery disease: a case‒control investigation with comparison to traditional biomarkers. Lipids Health Dis. 2022;21:126. doi:10.1186/s12944-022-01732-9
   PubMed Web of Science ®Google Scholar
• Wu TT, Gao Y, Zheng YY, et al. Atherogenic index of plasma (AIP): a novel predictive indicator for the coronary artery disease in postmenopausal women. Lipids Health Dis. 2018;17:197. doi:10.1186/s12944-018-0828-z
   PubMed Web of Science ®Google Scholar
• Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab. 2020;42:101092. doi:10.1016/j.molmet.2020.101092
   PubMed Web of Science ®Google Scholar
• Lambert JE, Ramos-Roman MA, Browning JD, et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146:726–735. doi:10.1053/j.gastro.2013.11.049
   PubMed Web of Science ®Google Scholar
• Hamlin AN, Chinnarasu S, Ding Y, et al. Low-density lipoprotein receptor-related protein-1 dysfunction synergizes with dietary cholesterol to accelerate steatohepatitis progression. J Biol Chem. 2018;293:9674–9684. doi:10.1074/jbc.RA118.001952
   PubMed Web of Science ®Google Scholar
• Zhou JH, Cai JJ, She ZG, et al. Noninvasive evaluation of nonalcoholic fatty liver disease: current evidence and practice. World J Gastroenterol. 2019;25:1307–1326. doi:10.3748/wjg.v25.i11.1307
   PubMed Web of Science ®Google Scholar